The Rate of Marrow Recovery and Extent of Donor Engraftment Following Transplantation of Ex Vivo–Expanded Bone Marrow Cells Are Independently Influenced by the Cytokines Used for Expansion
- 1 October 2005
- journal article
- research article
- Published by Mary Ann Liebert Inc in Stem Cells and Development
- Vol. 14 (5) , 564-575
- https://doi.org/10.1089/scd.2005.14.564
Abstract
Successful stem cell transplantation depends on cell dose, and this is particularly true for placental/ cord blood transplantation in which it has been clearly shown that both the success of engraftment as well as the speed of white cell and platelet recovery are dependent on the nucleated cell dose in the graft. Thus, if stem cell numbers could be increased, the speed as well as the likelihood of engraftment might be improved. We studied the effect of two different cytokine combinations— kit ligand (KL), interleukin-3 (IL-3), and Flt-3 ligand supplemented with thrombopoietin and IL- 11 (combination 1) or granulocyte/macrophage colony-stimulating factor (GM-CSF) and G-CSF (combination 2)—for their ability to affect speed and extent of engraftment using limited numbers (5 × 104) of murine bone marrow (BM) light-density (LD) cells or their progeny expanded ex vivo in the presence one or the other cytokine combination for 6 days. With combination 1, we found that speed of platelet recovery was enhanced, but at the expense of white blood cell (WBC) recovery and percent donor engraftment. Furthermore, the cytokine combination that best maintained donor engraftment, combination 2, did so at the expense of platelet recovery. In no case was percent donor engraftment improved over 5 × 104 unmanipulated LD BM cells. These results are consistent with the interpretation that immediate recovery of blood cells of different lineages and longterm donor engraftment are separate functions that can be influenced by the choice of cytokines used during the ex vivo expansion process.Keywords
This publication has 56 references indexed in Scilit:
- Preclinical ex vivo expansion of G-CSF-mobilized peripheral blood stem cells: effects of serum-free media, cytokine combinations and chemotherapyEuropean Journal of Haematology, 2005
- Augmentation of umbilical cord blood (UCB) transplantation with ex vivo–expanded UCB cells: results of a phase 1 trial using the AastromReplicell SystemBlood, 2003
- Adhesion of synchronized human hematopoietic progenitor cells to fibronectin and vascular cell adhesion molecule-1 fluctuates reversibly during cell cycle transit in ex vivo cultureBlood, 2002
- Role of different medium and growth factors on placental blood stem cell expansion: an in vitro and in vivo studyBone Marrow Transplantation, 2002
- Homing and engraftment defects in ex vivo expanded murine hematopoietic cells are associated with downregulation of β1 integrinExperimental Hematology, 2001
- Preclinical ex vivo expansion of cord blood hematopoietic stem and progenitor cells: duration of culture; the media, serum supplements, and growth factors used; and engraftment in NOD/SCID miceTransfusion, 2001
- A combination of megakaryocyte growth and development factor and interleukin-1 is sufficient to culture large numbers of megakaryocytic progenitors and megakaryocytes for transfusion purposesBritish Journal of Haematology, 1999
- Flt3L induces the ex-vivo amplification of umbilical cord blood committed progenitors and early stem cells in short-term culturesBritish Journal of Haematology, 1999
- PRESERVED LONG-TERM REPOPULATION AND DIFFERENTIATION PROPERTIES OF HEMATOPOIETIC GRAFTS SUBJECTED TO EX VIVO EXPANSION WITH STEM CELL FACTOR AND INTERLEUKIN 111Transplantation, 1999
- Clinical-scale human umbilical cord blood cell expansion in a novel automated perfusion culture systemBone Marrow Transplantation, 1998